NDA 219878 · Astrazeneca Ab
Baxfendy
Baxdrostat · Oral
NovelPriority reviewCDER novel approval, May 15, 2026: To treat hypertension in combination with other antihypertensive drugs
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 15, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
23
9 Phase 3, 3 recruiting
FAERS reports
273
83 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 7, 2026.
BAXFENDY, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure in adults who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction of these events with BAXFENDY. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the American College of Cardiology/American Heart Association (ACC/AHA). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe...
Mechanism: Baxdrostat is an inhibitor of human aldosterone synthase. Aldosterone contributes to hypertension by promoting the retention of sodium and water by the kidneys, which increases blood volume and, consequently, raises blood pressure. Aldosterone can cause vascular dysfunction, inflammation, and fibrosis. Inhibition of aldosterone synthase by baxdrostat decreases plasma aldosterone concentrations, thereby reducing blood pressure. Baxdrostat has a higher potency and selectivity for aldosterone synthase compared to the closely related enzyme 11β-hydroxylase (final enzyme in cortisol synthesis). In...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 15, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
2 products under this application
- BAXFENDY · BAXDROSTAT 1MG · TABLET, ORAL · Prescription
- BAXFENDY · BAXDROSTAT 2MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Baxdrostat" as an intervention, any sponsor and status, largest first.
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06677060 · 11,300 participants (planned) · Start Mar 14, 2025 · Primary completion Dec 17, 2029
Drug: Baxdrostat and dapagliflozin · For: Heart Failure
Sites: Birmingham, Alabama; Centreville, Alabama; Fairhope, Alabama · 977 sites in all
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressurePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06742723 · 5,000 participants (planned) · Start Mar 3, 2025 · Primary completion Dec 18, 2029
Drug: Baxdrostat/dapagliflozin; Placebo/dapagliflozin · For: Chronic Kidney Disease and Hypertension
Sites: Fairhope, Alabama; Sun City, Arizona; Tucson, Arizona · 771 sites in all
- A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06268873 · 2,554 participants · Start Mar 29, 2024 · Primary completion Feb 24, 2028
Drug: Baxdrostat/dapagliflozin; Dapagliflozin in combination with placebo · For: Chronic Kidney Disease and Hypertension
Sites: Fairhope, Alabama; Phoenix, Arizona; Surprise, Arizona · 565 sites in all
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06034743 · 796 participants · Start Nov 22, 2023 · Primary completion May 21, 2025
Drug: Baxdrostat; Placebo · For: Uncontrolled Hypertension; Resistant Hypertension
Sites: Saraland, Alabama; Scottsdale, Arizona; Sun City West, Arizona · 263 sites in all
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06344104 · 326 participants · Start Apr 8, 2024 · Primary completion Nov 24, 2025
Drug: Baxdrostat; Placebo · For: Uncontrolled Hypertension; Resistant Hypertension
Sites: Bahía Blanca, Argentina; CABA, Argentina; Ciudad de Buenos Aires, Argentina · 93 sites in all
- A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07686120 · 286 participants (planned) · Start Sep 17, 2026 · Primary completion Feb 9, 2028
Drug: baxdrostat 2mg; Placebo 2mg · For: Uncontrolled Hypertension
Sites: Beijing, China; Bengbu, China; Changchun, China · 51 sites in all
- Baxdrostat and Ventricular RemodelingPivotal-lookingNot yet recruiting
Subodh VermaAcademic, hospital or other
NCT07655362 · 286 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 30, 2028
Drug: Baxdrostat; Placebo · For: Cardiac Remodeling
Sites: North York, Canada; Toronto, Canada
- A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)Pivotal-lookingCompleted
CinCor Pharma, Inc.Industry
NCT04519658 · 275 participants · Start Oct 12, 2020 · Primary completion Jun 14, 2022
Drug: CIN-107; Placebo · For: Resistant Hypertension
Sites: Birmingham, Alabama; Saraland, Alabama; Tucson, Arizona · 80 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hyponatraemia26
- dizziness22
- muscle spasms21
- hyperkalaemia19
- blood potassium increased17
- blood sodium decreased14
- glomerular filtration rate decreased14
- headache14
- blood pressure increased12
- nausea12
- blood pressure decreased11
- hypotension10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 273 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Flack JM, Azizi M, Brown JM, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
Freeman MW, Halvorsen YD, Marshall W, et al. · N Engl J Med 2023 · Multicenter Study, Randomized Controlled Trial
- Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.
Azizi M, Brown JM, Dwyer JP, et al. · Lancet 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
Freeman MW, Bond M, Murphy B, et al. · Hypertens Res 2023 · Randomized Controlled Trial, Clinical Trial, Phase I
- Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors-A Systematic Review.
Rasmussen AA, Nordestgaard KL, Simonsen U, et al. · Basic Clin Pharmacol Toxicol 2025 · Systematic Review
- No Evidence of QTc Interval Prolongation With Baxdrostat Treatment: Concentration-QTc Modeling Assessment.
Sunnåker M, Källgren C, Parkinson J, et al. · Pharmacol Res Perspect 2025 · Randomized Controlled Trial, Clinical Trial, Phase I
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.